日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Review of Promising Off-Label Use of Deucravacitinib

对 Deucravacitinib 有前景的非适应症用途的回顾

Mima, Yoshihito; Yamamoto, Masako; Iozumi, Ken

Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment

四例结节性痒疹患者在接受度普利尤单抗治疗后仍出现持续性瘙痒或皮损,需要使用奈莫利珠单抗治疗。

Mima, Yoshihito; Yamamoto, Masako; Iozumi, Ken

The Absence of Recent Systemic Therapy can be a Significant Risk Factor for Nemolizumab-associated Cutaneous Adverse Events in Patients with Prurigo Nodularis: A Single-centre Retrospective Study

近期未接受全身治疗可能是结节性痒疹患者接受尼莫珠单抗治疗后发生皮肤不良事件的重要危险因素:一项单中心回顾性研究

Mima, Yoshihito; Yamamoto, Masako; Iozumi, Ken

Cutaneous Mass with Indurated Erythema in the Right Popliteal Fossa: A Quiz

右侧腘窝皮肤肿块伴硬结性红斑:小测验

Mima, Yoshihito; Yamamoto, Masako; Iozumi, Ken

Skin Erosion on the Nasal Root with Marked Right Eyelid Swelling: A Quiz

鼻根部皮肤糜烂伴右眼睑明显肿胀:一项测试

Mima, Yoshihito; Yamamoto, Masako; Iozumi, Ken

Cutaneous Adverse Events Following Nemolizumab Administration: A Review

Nemolizumab给药后皮肤不良事件:一项综述

Mima, Yoshihito; Yamamoto, Masako; Iozumi, Ken

Concurrent Nemolizumab-Induced Cutaneous Adverse Events and Asthma Exacerbation in a Patient With Prurigo Nodularis With Resolution of Both Conditions After Switching to Dupilumab

一名患有结节性痒疹的患者在使用奈莫利珠单抗治疗期间出现皮肤不良事件和哮喘加重,但在改用度普利尤单抗后两种疾病均得到缓解。

Mima, Yoshihito; Yamamoto, Masako; Iozumi, Ken

Tacrolimus Ophthalmic Suspension Can Be an Effective Treatment Option for Biologic-Induced Refractory Conjunctivitis

他克莫司滴眼液可作为生物制剂引起的难治性结膜炎的有效治疗选择

Mima, Yoshihito; Yamamoto, Masako; Iozumi, Ken

Long-Lasting Seborrheic Dermatitis Associated With Human Immunodeficiency Virus

与人类免疫缺陷病毒相关的长期脂溢性皮炎

Mima, Yoshihito; Yamamoto, Masako; Nonogaki, Akira; Iozumi, Ken

Trauma-Induced Psoriatic Arthritis: A Deep Köbner Phenomenon

创伤诱发的银屑病关节炎:一种深层的柯布纳现象

Mima, Yoshihito; Yamamoto, Masako; Nishida, Naoki; Norimatsu, Yuta; Iozumi, Ken